What is the optimal management approach for hepatocellular carcinoma based on tumor burden, liver function, and performance status?

Management of Hepatocellular Carcinoma

Use the BCLC (Barcelona Clinic Liver Cancer) staging system to guide treatment decisions, as it integrates tumor burden, liver function (Child-Pugh class), and performance status (ECOG) to link prognosis with evidence-based treatment allocation 1.

Staging Framework

The three critical prognostic factors that determine management are:

• Tumor burden: number/size of nodules, vascular invasion, extrahepatic spread
• Liver function: Child-Pugh class, bilirubin, albumin, portal hypertension, ascites
• Performance status: ECOG classification and cancer-related symptoms

1

Treatment Algorithm by Stage

Very Early/Early Stage (BCLC 0-A)

For solitary HCC <2 cm with compensated cirrhosis:

• Thermal ablation (radiofrequency or microwave) is first-line treatment 2
• Choice between ablation vs. resection depends on: tumor location, extent of portal hypertension, and performance status
• Both radiofrequency and microwave ablation are equally effective 2

For solitary HCC 2-3 cm:

• Thermal ablation can be considered as alternate first-line to surgery, based on tumor location, liver function, portal hypertension severity, and comorbidities 2

For up to 3 tumors <3 cm (not suitable for surgery):

• Thermal ablation is first-line treatment 2

Surgical resection indications:

• Single HCC in patients with preserved liver function
• Up to 3 lesions ≤3 cm 3

Liver transplantation:

• Recommended for multifocal HCC within accepted criteria with decompensated cirrhosis 2
• Absolute contraindications: vascular invasion and extrahepatic metastases 2
• Consider neoadjuvant locoregional therapy while on waiting list to reduce dropout from progression 2

Intermediate Stage (BCLC B)

Intra-arterial treatment (TAE, conventional TACE, or drug-eluting bead TACE) is standard of care 2.

Best candidates have:

• Limited tumor burden: solitary nodule <7 cm OR fewer than 4 tumors
• Preserved liver function: Child-Pugh A or B7 without ascites
• Good performance status: ECOG <2

2

Absolute contraindications to TACE/TAE:

• Decompensated liver disease
• Advanced kidney dysfunction
• Macroscopic vascular invasion
• Extrahepatic spread

2

Critical caveat: For large-volume intrahepatic disease, despite being intermediate-stage, consider systemic therapy or SIRT as first-line instead of TACE/TAE 2. Do NOT combine TA(C)E with multikinase inhibitors 2.

Advanced Stage (BCLC C)

Atezolizumab plus bevacizumab is the first-choice standard of care for systemic therapy 2.

Before initiating atezolizumab/bevacizumab:

• Assess for contraindications to either drug
• Evaluate variceal bleeding risk
• Patients with portal hypertension must have upper GI endoscopy within 6 months with adequately treated varices

2

Alternative first-line options (if contraindications exist or patient declines IV therapy):

• Sorafenib
• Lenvatinib (non-inferior overall survival to sorafenib)

2

For patients who progressed on sorafenib:

• Ramucirumab improved survival only in patients with AFP >400 ng/dL 1

Terminal Stage (BCLC D)

Characteristics:

• Severe liver dysfunction (Child-Pugh C) OR
• Severe cancer-related symptoms (ECOG PS >2)

Management: Symptomatic/supportive care 4

Key Clinical Pitfalls

1. Liver function trumps tumor stage: Across all treatment modalities, liver function is the primary determinant of prognosis, independent of tumor stage and performance status 5. Never compromise liver function for marginal oncologic benefit.

2. AFP does not rule out aggressiveness: Normal AFP levels do not exclude aggressive HCC or worse outcomes 1. However, AFP changes during treatment with atezolizumab/bevacizumab provide prognostic information 1.

3. Avoid treatment stage migration errors: Patients initially suitable for one BCLC stage treatment may need to move to next-stage treatments due to comorbidities, technical issues, or treatment failure 4.

4. Multidisciplinary assessment is mandatory: Avoid cognitive biases including excessive empiricism (over-weighting personal experience), excessive rationalism (rigid adherence to size cutoffs like 5.0 vs 5.1 cm), loss aversion (overweighting adverse event risk vs survival benefit), and lack of clustered principle (not considering multi-step treatment sequences) 1.

Emerging Considerations

Adjuvant therapy: Atezolizumab plus bevacizumab may improve recurrence-free survival after ablation, but longer-term follow-up is required before routine recommendation 2.

Stereotactic radiotherapy: Option for ablating tumors when surgery or conventional ablation not feasible 2.